Amneal Pharmaceuticals, Inc. has announced the US launch of four generic injectables after receiving US Food and Drug administration approval for dexamethasone sodium phosphate injection10 mg/ml, azacitidine 100mg, carboprost tromethamine injection 250 mcg/ml and atropine sulfate injection 0.5mg/5ml.
The company noted that atroprine had been granted competitive generic therapy status by the FDA, while dexamethasone and azacitidine are...




